You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
華潤醫藥(03320.HK)2020年營收達2004.23億港元 全年經調整純利升16.0%
格隆匯 03-26 12:44

格隆匯3月26日丨華潤醫藥(03320.HK)公佈2020年度業績,期內集團實現收益2004.23億港元,同比減少2.0%;公司擁有人應占溢利32.97億港元,同比增加0.3%;每股基本盈利0.52港元,宣派末期股息每股0.12港元。

2020年,集團積極應對政策變動和市場挑戰,大力推動研發創新,加快新興領域佈局,穩步推進外延發展與對外合作,持續優化業務結構與產品結構,加強資源統籌與整合協同,提升運營質量與效率。

按照人民幣口徑,報吿期間內集團總收益較上年同期減少1.2%。2020年製藥、醫藥分銷、藥品零售三個主要業務分部的收益佔比分別為14.6%、82.0%以及3.2%,2019年佔比分別為15.0%、81.7%以及3.2%。

期內集團實現毛利322.94億港元,同比減少5.1%(以人民幣口徑同比減少4.2%);整體毛利率為16.1%,與2019年的毛利率16.6%相比略下降0.5個百分點,主要因為報吿期間內製藥業務的平均毛利率有所下降,以及毛利率相對高的製藥業務收益佔比下降的綜合原因所致。

如剔除附屬公司處置收益及商譽減值等一次性項目影響,報吿期間內集團擁有人應占溢利同比實現增加16.0%(以人民幣口徑同比增加18.9%)。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account